GO:0001591 dopamine neurotransmitter receptor activity, coupled via Gi/Go: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001591 describes dopamine neurotransmitter receptor activity coupled to Gi/Go proteins, which typically inhibits adenylate cyclase and reduces cAMP.
• This activity is mediated primarily by the D2-like dopamine receptors: D2 (DRD2), D3 (DRD3), and D4 (DRD4) [2,3,7].
• Gi/Go coupling leads to inhibition of adenylyl cyclase, activation of G protein-gated inwardly rectifying potassium channels, and inhibition of voltage-gated calcium channels [2,3].
• D2-like receptor signaling is critical in motor control, reward, and cognition, and is implicated in Parkinson's disease, schizophrenia, and addiction.
• Regulation of Gi/Go signaling involves RGS proteins, which accelerate GTP hydrolysis and modulate receptor selectivity.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of Gi/Go-coupled dopamine receptor function in disease contexts.
Description
Dopamine neurotransmitter receptor activity coupled via Gi/Go (GO:0001591) is a molecular function that defines the ability of certain dopamine receptors to bind dopamine and activate heterotrimeric G proteins of the Gi/Go family, leading to inhibition of adenylyl cyclase and downstream changes in cellular activity. This activity is essential for modulating neuronal excitability, neurotransmitter release, and synaptic plasticity in the central nervous system [3,7]. The D2-like dopamine receptors, including D2 (DRD2), D3 (DRD3), and D4 (DRD4), are the primary mediators of this function [2,3]. Dysregulation of Gi/Go-coupled dopamine receptor signaling is associated with a range of neurological and psychiatric disorders, making it a key target for pharmacological and genetic research. Understanding the precise molecular mechanisms and regulatory pathways of GO:0001591 is critical for developing targeted therapies and for interpreting experimental models of dopamine-related diseases [5,7].
dopamine neurotransmitter receptor activity, coupled via Gi/Go At A Glance
| GO ID | GO:0001591 |
|---|---|
| GO term | dopamine neurotransmitter receptor activity, coupled via Gi/Go |
| Ontology | molecular_function |
| Synonym | dopamine D2 receptor activity, dopamine D3 receptor activity, dopamine D4 receptor activity |
| Major function | Binding dopamine and activating Gi/Go proteins to inhibit adenylyl cyclase and modulate ion channels |
| G protein coupling | Gi/Go family (Gαi, Gαo, Gαz) |
| Primary receptors | D2-like dopamine receptors: DRD2, DRD3, DRD4 |
| Downstream effectors | Adenylyl cyclase (inhibition), G protein-gated inwardly rectifying K+ channels, voltage-gated Ca2+ channels |
| Regulators | RGS proteins (e.g., RGS7, RGS9-2), Peroxiredoxin 6 |
What Is GO:0001591?
GO:0001591 is defined as the molecular function of combining with the neurotransmitter dopamine and activating adenylate cyclase via coupling to Gi/Go to initiate a change in cell activity. In practice, this means that when dopamine binds to a Gi/Go-coupled receptor, the receptor undergoes a conformational change that promotes the exchange of GDP for GTP on the Gαi/o subunit, leading to dissociation of the Gβγ dimer. The activated Gαi/o subunit then inhibits adenylyl cyclase, reducing intracellular cAMP levels, while the Gβγ dimer can directly modulate ion channels and other effectors [2,3]. This activity is distinct from dopamine receptors coupled to Gs (which stimulate adenylyl cyclase) or Gq (which activate phospholipase C).
Why Is dopamine neurotransmitter receptor activity, coupled via Gi/Go Important in Cell Biology?
GO:0001591 is fundamental to understanding how dopamine modulates neuronal activity and behavior. Gi/Go-coupled dopamine receptors are major targets for antipsychotic and anti-Parkinsonian drugs, and their dysfunction is linked to schizophrenia, addiction, and movement disorders. The ability to precisely manipulate these receptors using CRISPR-based approaches enables researchers to dissect their roles in health and disease, and to validate therapeutic targets.
• Controls motor function through modulation of basal ganglia circuits.
• Regulates reward and motivation pathways in the mesolimbic system.
• Influences cognition and working memory in the prefrontal cortex.
• Implicated in Parkinson's disease, schizophrenia, and bipolar disorder.
• Target of antipsychotic drugs (e.g., haloperidol, risperidone) and anti-Parkinsonian drugs (e.g., pramipexole).
• Modulates neurotransmitter release via presynaptic autoreceptors.
• Regulates ion channel activity, affecting neuronal excitability.
• Subject to regulation by RGS proteins and kinases.
• Key to understanding drug addiction and reward processing.
• Provides a model for studying G protein-coupled receptor (GPCR) signaling specificity.
What Happens During dopamine neurotransmitter receptor activity, coupled via Gi/Go?
Dopamine Binding and Receptor Activation
In simple terms: Dopamine binds to the receptor, causing it to change shape and activate a G protein inside the cell.
The process begins when dopamine binds to the orthosteric site of a D2-like dopamine receptor (DRD2, DRD3, or DRD4). This binding induces a conformational change in the receptor that enables it to act as a guanine nucleotide exchange factor (GEF) for the Gαi/o subunit of an associated heterotrimeric G protein. The receptor's activation is highly specific; for example, the human D3 receptor expressed in AtT-20 cells can be activated by dopamine to inhibit P/Q-type calcium channels.
G Protein Activation and Effector Modulation
In simple terms: The activated G protein splits into two parts that go on to inhibit enzymes and open ion channels.
Upon receptor activation, the Gαi/o subunit exchanges GDP for GTP and dissociates from the Gβγ dimer. The GTP-bound Gαi/o subunit directly inhibits adenylyl cyclase, reducing cAMP production. The free Gβγ dimer can activate G protein-gated inwardly rectifying potassium (GIRK) channels and inhibit voltage-gated calcium channels, leading to decreased neuronal excitability and neurotransmitter release. This dual signaling mechanism allows for fine-tuned control of cellular activity.
Signal Termination and Regulation
In simple terms: The signal is turned off when the G protein hydrolyzes GTP, a process sped up by RGS proteins.
The intrinsic GTPase activity of Gαi/o hydrolyzes GTP to GDP, returning the G protein to its inactive state and allowing the subunits to reassociate. This process is accelerated by Regulators of G protein Signaling (RGS) proteins, such as RGS7 and RGS9-2, which act as GTPase-activating proteins (GAPs). Additionally, receptor desensitization and internalization can terminate signaling. Peroxiredoxin 6 has been shown to mediate Gαi protein-coupled receptor inactivation by cJun kinase, providing another layer of regulation.
Heteromerization and Crosstalk
In simple terms: Dopamine receptors can pair with other receptors, changing how they signal.
D2-like dopamine receptors can form heteromers with other GPCRs, which alters their signaling properties. For instance, heteromerization of dopamine D1 and histamine H3 receptors leads to marked changes in signal transduction. Similarly, heteromeric association can create novel receptor complexes with altered pharmacology, as seen with P2Y-like adenosine receptors. These interactions add complexity to the regulation of GO:0001591 activity.
Key Genes Involved in GO:0001591 dopamine neurotransmitter receptor activity, coupled via Gi/Go
The following genes encode the receptors, G proteins, and regulatory proteins that mediate or modulate dopamine neurotransmitter receptor activity coupled via Gi/Go.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DRD2 | D2 dopamine receptor; primary Gi/Go-coupled receptor | Target of antipsychotics; implicated in schizophrenia and addiction |
| DRD3 | D3 dopamine receptor; Gi/Go-coupled receptor | Inhibits P/Q-type calcium channels; involved in mood and reward |
| DRD4 | D4 dopamine receptor; Gi/Go-coupled receptor | Associated with attention and novelty seeking; potential drug target |
| GNAI1 | Gαi1 subunit; inhibits adenylyl cyclase | Mediates Gi signaling; knockout models available |
| GNAI2 | Gαi2 subunit; inhibits adenylyl cyclase | Widely expressed; involved in neuronal signaling |
| GNAI3 | Gαi3 subunit; inhibits adenylyl cyclase | Modulates GPCR signaling |
| GNAO1 | Gαo subunit; major neuronal G protein | Highly expressed in brain; mutations cause neurological disorders |
| GNB1 | Gβ1 subunit; part of Gβγ dimer | Modulates ion channels and effectors |
| GNG2 | Gγ2 subunit; part of Gβγ dimer | Regulates G protein signaling |
| RGS7 | Regulator of G protein signaling 7 | Modulates Gi/Go signaling; component of RGS7-Gβ5 complex |
| RGS9 | Regulator of G protein signaling 9 | Accelerates GTP hydrolysis; involved in striatal signaling |
| PRDX6 | Peroxiredoxin 6 | Mediates Gαi inactivation via cJun kinase |
| ADCY1 | Adenylyl cyclase 1 | Effector inhibited by Gαi; modulates cAMP |
| ADCY5 | Adenylyl cyclase 5 | Striatal adenylyl cyclase; inhibited by Gi |
| KCNJ3 | GIRK1 potassium channel subunit | Activated by Gβγ; modulates excitability |
| KCNJ6 | GIRK2 potassium channel subunit | Forms GIRK channels with GIRK1 |
| CACNA1B | P/Q-type calcium channel subunit | Inhibited by D3 receptor activation |
How Is dopamine neurotransmitter receptor activity, coupled via Gi/Go Regulated?
The activity of GO:0001591 is tightly regulated at multiple levels. RGS proteins, such as RGS7 and RGS9-2, act as GTPase-activating proteins for Gαi/o, accelerating signal termination and dictating receptor-G protein selectivity. Peroxiredoxin 6 has been shown to mediate Gαi protein-coupled receptor inactivation by cJun kinase, linking oxidative stress and kinase signaling to receptor desensitization. Additionally, heteromerization with other GPCRs can alter the signaling properties of D2-like receptors, as demonstrated for D1-H3 heteromers and P2Y-like adenosine receptors. These regulatory mechanisms ensure precise control of dopamine signaling in response to physiological demands.
dopamine neurotransmitter receptor activity, coupled via Gi/Go and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DRD2 | Parkinson's disease, schizophrenia, addiction | DRD2 knockout mice; point mutation of D2 receptor in striatal neurons |
| DRD3 | Schizophrenia, mood disorders | DRD3 knockout mice; D3 receptor overexpression in AtT-20 cells |
| DRD4 | Attention deficit hyperactivity disorder (ADHD) | DRD4 knockout mice; human D4 receptor knock-in |
| GNAO1 | Neurological disorders with movement abnormalities | GNAO1 knockout or point mutation knock-in mice |
| RGS9 | Striatal dysfunction, addiction | RGS9 knockout mice; RGS9 overexpression in striatum |
Parkinson's Disease
Parkinson's disease is characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor deficits. Gi/Go-coupled D2 receptors are critical for motor control, and their modulation is a mainstay of Parkinson's therapy. D2 receptor agonists like pramipexole directly activate these receptors to alleviate symptoms.
Schizophrenia
Schizophrenia is associated with dopaminergic dysfunction, particularly in the mesolimbic and mesocortical pathways. D2 receptor antagonists are effective antipsychotics, highlighting the role of Gi/Go-coupled dopamine receptors in psychosis. Genetic variations in DRD2 and DRD3 have been linked to schizophrenia risk.
Addiction and Reward
Dopamine D2 receptors in the nucleus accumbens modulate reward and reinforcement. Reduced D2 receptor availability is associated with addiction vulnerability. Gi/Go signaling in these circuits is essential for reward processing and drug-seeking behavior.
From dopamine neurotransmitter receptor activity, coupled via Gi/Go-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does DRD2 mediate Gi/Go signaling in vivo? | DRD2 knockout mouse; conditional knockout in specific brain regions |
| How does a point mutation in DRD3 affect ligand binding? | DRD3 point-mutation knock-in mouse or cell line |
| What is the effect of DRD4 overexpression on behavior? | DRD4 overexpression transgenic mouse or viral vector |
| Can we tag endogenous DRD2 to track its localization? | DRD2 tagged knock-in mouse (e.g., HA or GFP tag) |
| Does RGS9 regulate D2 receptor signaling? | RGS9 knockout mouse; RGS9 overexpression in striatal neurons |
| How does GNAO1 mutation affect neuronal excitability? | GNAO1 point-mutation knock-in mouse; electrophysiology |
How to Study the dopamine neurotransmitter receptor activity, coupled via Gi/Go Process
| Method | What It Measures | Typical Application |
|---|---|---|
| GTPγS binding | G protein activation | Pharmacological profiling of D3 receptor agonists |
| cAMP assay | Intracellular cAMP levels | Measuring Gi-mediated inhibition of adenylyl cyclase |
| Patch-clamp electrophysiology | Ion channel activity | Assessing D3 receptor inhibition of calcium channels |
| BRET/FRET | Protein-protein interactions and conformational changes | Real-time monitoring of G protein activation |
| Immunoprecipitation | Protein complexes | Studying heteromerization of dopamine receptors |
| RNA-seq | Gene expression changes | Transcriptomic profiling after receptor activation |
| CRISPR knockout | Gene function | Validating role of DRD2 in Gi/Go signaling |
| Phosphoproteomics | Phosphorylation events | Identifying downstream signaling nodes |
GTPγS Binding Assays
Agonist-induced [35S]GTPγS binding is a classic method to measure G protein activation by Gi/Go-coupled receptors. This assay can be performed on membranes from cells expressing human D3 dopamine receptors, as demonstrated by Pregenzer et al.. It allows quantification of receptor-mediated G protein activation and is useful for pharmacological profiling.
cAMP Assays
Since Gi/Go activation inhibits adenylyl cyclase, measuring intracellular cAMP levels (e.g., via ELISA or FRET-based sensors) provides a direct readout of receptor activity. This method is widely used to study D2-like receptor function and the effects of mutations.
Electrophysiology
Patch-clamp recordings can measure the modulation of ion channels (e.g., GIRK, calcium channels) downstream of Gi/Go activation. For example, activation of human D3 receptors inhibits P/Q-type calcium channels and secretory activity in AtT-20 cells. This technique is essential for understanding the physiological consequences of receptor activation.
BRET/FRET Biosensors
Bioluminescence resonance energy transfer (BRET) and fluorescence resonance energy transfer (FRET) biosensors can monitor real-time G protein activation, subunit dissociation, and receptor conformational changes in living cells. These methods have been used to study RGS protein complexes and their selectivity for Gi/Go-coupled receptors.
How CRISPR Can Be Used to Study GO:0001591 dopamine neurotransmitter receptor activity, coupled via Gi/Go
Knockout
CRISPR knockout of DRD2, DRD3, or DRD4 in cell lines or animal models abolishes Gi/Go-coupled dopamine receptor activity, enabling researchers to study loss-of-function phenotypes. For example, DRD2 knockout mice exhibit altered motor and reward behaviors. Knockout of Gαi/o subunits can also be used to dissect G protein specificity.
Point Mutation
Introducing point mutations in DRD2, DRD3, or DRD4 can mimic disease-associated variants or disrupt ligand binding, G protein coupling, or receptor trafficking. For instance, mutations in the DRD2 gene have been linked to schizophrenia risk. Point mutations in GNAO1 can cause neurological disorders and can be modeled using CRISPR knock-in.
Knock-in
Knock-in of tagged receptors (e.g., HA-tagged DRD2) allows for precise localization and interaction studies in endogenous contexts. Knock-in of human DRD4 into mouse models can help study species-specific pharmacology. CRISPR knock-in of disease-associated mutations in DRD3 or GNAO1 provides valuable models for drug discovery.
Overexpression
Overexpression of DRD2, DRD3, or DRD4 using CRISPR activation (CRISPRa) or viral vectors can enhance Gi/Go signaling and mimic pathological states such as addiction or schizophrenia. Overexpression of RGS9 can modulate receptor desensitization. These models are useful for studying gain-of-function effects and for screening potential therapeutics.
How EDITGENE Supports dopamine neurotransmitter receptor activity, coupled via Gi/Go Research
Researchers studying dopamine neurotransmitter receptor activity, coupled via Gi/Go-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, disease pathology, or drug response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional validation of genes such as DRD2, DRD3, DRD4, and their downstream effectors.
Contact EDITGENE today to design your custom CRISPR model for dopamine neurotransmitter receptor activity, coupled via Gi/Go research.
Frequently Asked Questions About dopamine neurotransmitter receptor activity, coupled via Gi/Go
What is GO:0001591?
GO:0001591 is a Gene Ontology molecular function term that describes dopamine neurotransmitter receptor activity coupled via Gi/Go proteins. It involves binding dopamine and activating Gi/Go to inhibit adenylyl cyclase and modulate cellular activity.
What genes are involved in dopamine neurotransmitter receptor activity, coupled via Gi/Go?
The primary genes are DRD2, DRD3, and DRD4, which encode the D2-like dopamine receptors. Downstream effectors include GNAI1, GNAI2, GNAI3, GNAO1, and regulators like RGS7 and RGS9 [2,3,5].
How does Gi/Go coupling affect neuronal function?
Gi/Go coupling inhibits adenylyl cyclase, reduces cAMP, activates GIRK channels, and inhibits voltage-gated calcium channels, leading to decreased neuronal excitability and neurotransmitter release [2,3].
What diseases are associated with Gi/Go-coupled dopamine receptors?
They are implicated in Parkinson's disease, schizophrenia, addiction, and mood disorders. D2 receptor antagonists are used to treat schizophrenia, while D2 agonists are used for Parkinson's disease.
What is the difference between D1 and D2 dopamine receptors?
D1-like receptors (D1, D5) couple to Gs and stimulate adenylyl cyclase, while D2-like receptors (D2, D3, D4) couple to Gi/Go and inhibit adenylyl cyclase.
How can I study Gi/Go-coupled dopamine receptor signaling?
Common methods include GTPγS binding assays, cAMP assays, electrophysiology, and BRET/FRET biosensors. CRISPR knockout and knock-in models are also valuable for functional studies [3,5,8].
What are RGS proteins and how do they regulate dopamine receptors?
RGS (Regulator of G protein Signaling) proteins accelerate GTP hydrolysis on Gα subunits, thereby terminating signaling. RGS7 and RGS9-2 are known to regulate Gi/Go-coupled dopamine receptors.
Can CRISPR be used to model dopamine receptor mutations?
Yes, CRISPR can introduce precise point mutations, knockouts, or knock-ins in DRD2, DRD3, DRD4, and G protein genes to model disease-associated variants or study receptor function.
What is the role of peroxiredoxin 6 in Gi/Go signaling?
Peroxiredoxin 6 mediates Gαi protein-coupled receptor inactivation by cJun kinase, linking oxidative stress to receptor desensitization.
How does heteromerization affect dopamine receptor signaling?
Heteromerization with other GPCRs can alter ligand binding, G protein coupling, and downstream signaling. For example, D1-H3 heteromers show marked changes in signal transduction.
Conclusion
GO:0001591, dopamine neurotransmitter receptor activity coupled via Gi/Go, is a central molecular function in dopaminergic signaling, mediated primarily by D2-like receptors. Its dysregulation contributes to major neurological and psychiatric disorders, making it a critical target for research and drug development. Advances in CRISPR-based models and signaling assays continue to unravel the complexities of this pathway, offering new opportunities for therapeutic intervention.
References
- 1. Schattauer SS et al.. 2017. Peroxiredoxin 6 mediates Gαi protein-coupled receptor inactivation by cJun kinase.. Nat Commun 8(1):743 PMID: 28963507
- 2. Obadiah J et al.. 1999. Adenylyl cyclase interaction with the D2 dopamine receptor family; differential coupling to Gi, Gz, and Gs.. Cell Mol Neurobiol 19(5):653-64 PMID: 10384262
- 3. Kuzhikandathil EV et al.. 1999. Activation of human D3 dopamine receptor inhibits P/Q-type calcium channels and secretory activity in AtT-20 cells.. J Neurosci 19(5):1698-707 PMID: 10024356
- 4. Ferrada C et al.. 2009. Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors.. Br J Pharmacol 157(1):64-75 PMID: 19413572
- 5. Masuho I et al.. 2013. Macromolecular composition dictates receptor and G protein selectivity of regulator of G protein signaling (RGS) 7 and 9-2 protein complexes in living cells.. J Biol Chem 288(35):25129-25142 PMID: 23857581
- 6. Yoshioka K et al.. 2001. Heteromeric association creates a P2Y-like adenosine receptor.. Proc Natl Acad Sci U S A 98(13):7617-22 PMID: 11390975
- 7. Robinson SE et al.. 2017. Dopamine D2 Receptors Modulate Pyramidal Neurons in Mouse Medial Prefrontal Cortex through a Stimulatory G-Protein Pathway.. J Neurosci 37(42):10063-10073 PMID: 28912160
- 8. Pregenzer JF et al.. 1997. Agonist-induced [35S]GTPgammaS binding in the membranes of Spodoptera frugiperda insect cells expressing the human D3 dopamine receptor.. Neurosci Lett 226(2):91-4 PMID: 9159497
